InvestSMART

LTR Pharma Ltd (ASX:LTP)

ALERT: Price-sensitive ASX Announcement for LTP
Current share price for LTP : $0.505 0 (0%)+
Announcement
Release
29 Aug 2025 8:49AM
Price at Release
$0.505
Full Release
download
Summary
LTR Pharma Ltd reported its FY25 results, highlighting significant achievements in both clinical and commercial milestones. The company secured a global co-development agreement with Aptar Pharma and expanded its product portfolio with ROXUS® and OROFLOW®. They also successfully initiated patient treatments under Australia's TGA special access schemes and established extensive distribution networks. Financially, LTR Pharma maintained a strong cash balance of $31.8 million and saw a significant increase in revenue, primarily from R&D tax incentives. Operational highlights include the successful clinical validation of SPONTAN® with a 470% faster absorption rate compared to oral vardenafil tablets.
Key Points
  • SPONTAN® achieved 470% faster absorption rate than oral vardenafil tablets.
  • Secured global Co-Development Agreement with Aptar Pharma.
  • Expanded product development portfolio with ROXUS® and OROFLOW®.
  • Established national distribution through Symbion and Men's Health Downunder.
  • Maintained a cash balance of $31.8 million as of 30 June 2025.
  • Increased revenue to $2.1 million due to R&D tax incentives.
  • Initiated patient treatment under TGA special access schemes.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.